4 results
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
To study the effect on intraocular pressure in patients using the Travalert dosing aid with or without the additional use of the Eyot and with of without additional patient education.
This study aims to assess the safety and user acceptance (comfort and satisfaction with pumping program) of a modified Symphony program card, the INITIATE 2.0.